February 1st 2023
Health care expert and lived experience panels came to a consensus on several aspects that should be considered in the decision to offer and continue active surveillance for prostate cancer.
January 26th 2023
The report also suggests that ataxia telangiectasia and Rad3-related protein inhibition could be a valuable tool to overcome resistance.
January 23rd 2023
The report suggests that high-resolution micro-ultrasound could help identify clinically significant lesions that would be missed with conventional MRI.
January 14th 2023
The importance of identifying rare pathogenic mutations and genetic risk score among patients was explored in this new analysis, with goals that included reducing mortality and early disease detection.
January 13th 2023
A meta-analysis supported that Black men have similar or better prostate cancer outcomes compared with White men when health care access is equal and treatment is standardized for all patients.
Latest ACS Cancer Statistics Report Highlights Alarming Trends, Disparities in Prostate Cancer
Following the release of its 2023 report on cancer statistics, the American Cancer Society announced a new initiative to improve prostate cancer outcomes and reduce disparities.
FDA Approves Darolutamide Combo for Metastatic Hormone-Sensitive Prostate Cancer
Darolutamide, sold as Nubeqa, is an androgen receptor inhibitor, which works to limit prostate cell growth by preventing the binding of hormones, or androgens, to proteins known as androgen receptors.
Age, Education Level Shown to Influence Genomic Profiling Adherence in Patients With Metastatic Genitourinary Cancers
Reasons for pursuing genomic profiling among patients with advanced bladder, renal, and prostate cancers included guiding treatment and improving treatment response, in which age and education level were found to significantly influence shared decision-making.
CVD Risk Associated With ADT in Prostate Cancer
Focusing on available agents in prostate cancer, experts consider how androgen deprivation therapy impacts risk of cardiovascular disease.
An Overview of the Prostate Cancer Treatment Landscape
A comprehensive review of the therapeutic classes available for patients with prostate cancer.
Correlation Between Prostate Cancer and Cardiovascular Disease
Shared insight on the correlation between prostate cancer and cardiovascular disease, with a focus on the attributes that increase a patient’s risk.
Prostate Cancer’s Impact on Economy and Life
A broad look at the economic burden of prostate cancer and outlook in regard to survival within the current treatment landscape.
Understanding the Clinical Burden of Prostate Cancer
Expert perspectives on prostate cancer with deference to clinical presentations, diagnosis, and prognosis.
Experts Discuss PARP Inhibition in Prostate and Ovarian Cancers
Experts in gynecologic oncology and genitourinary oncology discuss the current state of PARP inhibitors in prostate and ovarian cancers.
Dr Ashley Ross on Genomic Testing Patients Post Prostatectomy
Ashley Ross, MD, PhD, urologist and associate professor at the Northwestern University Feinberg School of Medicine provides insight into genomic testing in postprostatectomy patients.
Bayer, Orion Announce Expansion of Nubeqa Development Program
Bayer and Orion corporation today announced the upcoming expansion of the global clinical development program for darolutamide (Nubeqa), an oral androgen receptor inhibitor for patients with prostate cancer.
MRI and Targeted Biopsy as Accurate as Current Standard for Prostate Cancer Diagnosis
Results from the phase 3 PRECISE trial showed that MRI with targeted biopsies matched or exceeded the accuracy of the current standard for detecting clinically significant prostate cancer.
Dr Ashley Ross on the Potential for Targeted Therapies Earlier in Prostate Cancer Treatment
Ashley Ross, MD, urologist and associate professor at the Northwestern University Feinberg School of Medicine, gives insight on the potential for PARP inhibitors in earlier disease settings for prostate cancer.
Study Finds Shorter Radiation Regimen Safe, Effective for Advanced Prostate Cancer
Shortening a traditional 45-day course of radiation therapy to 5 days of stereotactic body radiotherapy for patients with advanced, high-risk prostate cancer is safe and effective, a study from UCLA Jonsson Comprehensive Cancer Center found.
Dr Ashley Ross on the Changing Treatment Landscape of Prostate Cancer
Ashley Ross, MD, PhD, urologist and associate professor at the Northwestern University Feinberg School of Medicine, discusses the increasingly dynamic treatment landscape in prostate cancer.
Mediterranean Diet Might Benefit Low-Risk Prostate Cancer Patients
A recent study from the University of Texas MD Anderson Cancer Center found that men with localized prostate cancer on active surveillance might benefit from following a Mediterranean-style diet.
Prostate Cancer Tumor Size Often Underestimated by MRI, Study Finds
Magnetic resonance imaging (MRI) is often used in the diagnosis and management of prostate cancer, but the method frequently underestimates tumor size, a study in the Journal of Urology shows.
Dr Luis Carrascosa on Innovations in Radiation Therapy for Prostate Cancer
Luis Carrascosa, MD, a radiation oncologist at the Florida Cancer Specialists Ocala Cancer Center, discusses new and upcoming trends in radiation therapy for prostate cancer.
Innovative Procedure Minimizes Potential Prostate Cancer Radiation Side Effects
Florida Cancer Specialists has integrated SpaceOAR Hydrogel into its armamentarium as a pre-treatment for radiation therapy in prostate cancer patients.
What Is Clinical Utility in a Tumor Biomarker Test? Former ASCO President Knows It When He Sees It
Daniel F. Hayes, MD, offers definitions and an algorithm for clinicians to define clinical utility.
Huge Prostate Cancer Genetics Study Highlights Disparities in Risk, Research
The findings could lead to a precision medicine approach to prostate cancer screening.
Dr Neeraj Agarwal on Knowledge Gaps and Genomic Testing in Prostate Cancer
Neeraj Agarwal, MD, University of Utah Huntsman Cancer Institute, discusses knowledge gaps and the importance of genomic testing in prostate cancer.
Dr Neeraj Agarwal on Who Can Benefit from PARP Inhibition
Neeraj Agarwal, MD, University of Utah Huntsman Cancer Institute, shares his experience regarding the prostate cancer patients who could potentially benefit from PARP inhibition.
What We’re Reading: Congress Delays Start of RO Model; Examining Novel COVID-19 Strain; Pandemic Death Rates
Congress passes legislation that will delay the start of the Radiation Oncology (RO) Advanced Payment Model; examining the newly identified variant of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19); a study finds Hispanics and those without college degrees most subject to excess death during pandemic.
What We’re Reading: Genomic Indicators Predict Prostate Cancer Outcomes; FDA Authorizes At-Home COVID-19 Test; Herd Immunity Possible by Spring 2021
Samples show certain subgroups of men with prostate cancer are more receptive to radiation therapy; FDA grants emergency use authorization to an at-home coronavirus disease 2019 (COVID-19) test; Anthony Fauci, MD, says COVID-19 herd immunity is possible by spring 2021.
Dr Neeraj Agarwal on PARP Inhibitor Combination Treatments for Prostate Cancer
Neeraj Agarwal, MD, a clinician and researcher at the University of Utah Huntsman Cancer Institute, discusses investigational combinations with PARP inhibitors in prostate cancer treatment.
Research Finds 2 New Targets for Prostate Cancer Therapies
The genes are part of the family that cause cancer cells to grow.
Dr Neeraj Agarwal Discusses PARP Inhibitors as First-Line Prostate Cancer Treatment
Neeraj Agarwal, MD, of the University of Utah's Huntsman Cancer Institute, discusses ongoing trials of PARP inhibitors as first-line metastatic prostate cancer treatments.
Prostate Cancer Cohort Shows Where Active Surveillance Presents Lowest Risk
Researchers from the University of California San Francisco published their results in the Journal of Urology.
Dr Neeraj Agarwal on Why PARP Inhibitor Approval in Prostate Cancer Is Slow-Moving
Neeraj Agarwal, MD, of the University of Utah's Huntsman Cancer Institute, discusses challenges to progress in getting FDA approval for PARP inhibitors in prostate cancer.
2 Clarke Drive Cranbury, NJ 08512